Though the exact mechanisms by which monocytic differentiation leads to venetoclax resistance are yet to be elucidated, our data suggest that IFNγ signaling may play a pivotal role and is a potential therapeutic target in venetoclax resistance in AML. This evidence concerns the gene IFNG and acute myeloid leukemia.